Jubilant Life gets USFDA nod for hypertension drug

In a BSE filing, the company said it has received abbreviated new drug application (ANDA) final approval for olmesartan medoxomil tablets - 5 mg, 20 mg, and 40 mg.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news